Antiangiogenic therapy accelerates tumor metastasis

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 24-26

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Metastasis; Tumor progression

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; ENDOSTATIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; DRUG TARGETING; EDITORIAL; GLIOBLASTOMA; HEART METASTASIS; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MICROMETASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENT CANCER; SOLID TUMOR;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ENDOSTATINS; HUMANS; MICE; NEOPLASM METASTASIS;

EID: 78650116154     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.038     Document Type: Editorial

References (31)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:49-53.
3. Sugarbaker E.V., Thornthwaite J., Ketchan A.S. Inhibitory effect of a primary tumor on metastasis. Progress in cancer research and therapy 1977, 227-240. Raven Press, New York. S.B. Day, W.P.L. Myers, P. Stansly, S. Garattini, M.G. Lewis (Eds.).
4. Rastinejad F., Polverini P.J., Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56:345-355.
5. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
6. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasioos G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
7. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
8. Nordern A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity and patterns of recurrence. Neurology 2008, 70:779-787.
9. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727.
10. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
11. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
12. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., Hallin M.E., Wickman G.R., Amundson K., et al. Non-clinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinase 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283.
13. Padera T.P., Kuo A.H., Hoshida T., Liao S., Lobo J., Kozar K.R., et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Res 2008, 7:2272-2279.
14. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
15. Paez-Ribes M., Allen A., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:222-231.
16. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
17. Wilhelm S.M., Adnane L., Newell P., Villanueva A., llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
18. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104:17069-17074.
19. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
20. Saidi A., Hagedorn M., Allain N., Verpelli C., Sala C., Bello L., et al. Combined targeting of interleukin 6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 2009, 125:1054-1064.
21. Cairns R.A., Khokha R., Hill R.P. Molecular mechanisms of tumor growth and metastasis: an integrated view. Curr Mol Med 2003, 3:659-671.
22. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006, 116:642-651.
23. Roskoski R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007, 356:323-328.
24. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2008, 110:173-180.
25. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stravrou D., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
26. Medioni J., Choueri T.K., Zinzindohoue F., Cho D., Fournier L., Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol 2009, 181:2470-2475.
27. Szmit S., Zagrodzka M., Kurzyna M., Opolaki G., Szczylik C. Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma. Cardiology 2009, 114:67-71.
28. Fokt R.M., Templeton A., Gillesen S., Ohlschlegel C., Schmid H.P. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int 2009, 83:122-124.
29. Koutras A.K., Krikelis D., Alexandrou N., Starakis I., Kalofonos H.P. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 2007, 27:4255-4257.
30. Zwolak P., Jasinski P., Terai K., Gallus N.J., Ericson M.E., Clohisy D.R., et al. Addition of receptor tyrosine kinase inhibitor to radiation increases tumor control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 2008, 44:2506-2517.
31. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:755-766.